QBiotics Group Limited
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Multiple Therapeutics
QBiotics Group Limited is an Australian clinical stage life sciences company focused on discovering and developing novel small molecule pharmaceuticals derived from natural sources using its proprietary EcoLogic™ biodiscovery platform. Its pipeline targets oncology and wound healing. Lead asset tigilanol tiglate (EBC 46) is an intratumoural therapy in Phase II trials for solid tumours. It is commercialised as STELFONTA® in veterinary oncology, providing real world validation. EBC 1013 is a topically applied regenerative wound therapy in Phase I/IIa clinical studies. QBiotics employs a capital efficient model integrating discovery, phenotypic screening and veterinary validation to de risk development. Its strategy is to advance programmes to Phase II proof of concept in human clinical studies, and then pursue strategic partnering to accelerate to late stage development and commercialisation.
.jpg)
Company HQ City:
Toowong BC
Company HQ State:
Queensland
Company HQ Country:
Australia
Year Founded:
In 2017, EcoBiotics and QBiotics merged to form the QBiotics Group.
Lead Product in Development:
Tigilanol tiglate (EBC 46), is an intratumoural small molecule therapy undergoing Phase II clinical trials for solid tumours including soft tissue sarcoma and head and neck cancer.
The compound has also been commercialised in veterinary medicine as STELFONTA®, providing real world validation of the platform.
CEO
Ebru Davidson, Interim CEO and Managing Director
Dr Victoria Gordon, Executive Director, Chief Strategy Officer and Co-Founder
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
Head & Neck cancer trial final data read-out — Q2 CY26
Interim data from wound healing trial — Q4 CY26
Breast cancer trial (sponsored by Unicancer) recruitment opens — Q4 CY26
What is your next catalyst (value inflection) update?
Head & Neck cancer trial final data read-out — Q2 CY26
Interim data from wound healing trial — Q4 CY26
Breast cancer trial (sponsored by Unicancer) recruitment opens — Q4 CY26
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}